These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15025411)

  • 1. Managing hematologic toxicities: novel therapies.
    Nirenberg A
    Cancer Nurs; 2003 Dec; 26(6 Suppl):32S-37S. PubMed ID: 15025411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin.
    Collantes RS; Younossi ZM
    J Clin Gastroenterol; 2005 Jan; 39(1 Suppl):S9-13. PubMed ID: 15597026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
    Ong JP; Younossi ZM
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S17-21. PubMed ID: 15468613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New generation cytokines to prevent anemia and febrile neutropenia].
    Fayette J; Blay JY
    Bull Cancer; 2006 May; 93(5):483-7. PubMed ID: 16777626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
    Younossi ZM; Nader FH; Bai C; Sjogren R; Ong JP; Collantes R; Sjogren M; Farmer D; Ramsey L; Terra K; Gujral H; Gurung C; Srishord M; Fang Y
    J Viral Hepat; 2008 May; 15(5):370-8. PubMed ID: 18194172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
    Patton J; Reeves T; Wallace J
    Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.
    Biganzoli L; Untch M; Skacel T; Pico JL
    Semin Oncol; 2004 Jun; 31(3 Suppl 8):27-34. PubMed ID: 15181606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of supportive-care agents for patients with cancer.
    Neumann TK; Foote M
    Biotechnol Annu Rev; 2003; 9():397-417. PubMed ID: 14650936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L; Shiffman R; Tomita D; Stolshek B; Rossi G; Adamson R
    Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response.
    Persson U; Borg S; Jansson S; Ekman T; Franksson L; Friesland S; Larsson AM
    Adv Ther; 2005; 22(3):208-24. PubMed ID: 16236682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
    Miller AA; Wang XF; Gu L; Hoffman P; Khatri J; Dunphy F; Edelman MJ; Bolger M; Vokes EE; Green MR;
    J Thorac Oncol; 2008 Oct; 3(10):1159-65. PubMed ID: 18827613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
    Crawford J
    Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
    Burstein HJ; Parker LM; Keshaviah A; Doherty J; Partridge AH; Schapira L; Ryan PD; Younger J; Harris LN; Moy B; Come SE; Schumer ST; Bunnell CA; Haldoupis M; Gelman R; Winer EP
    J Clin Oncol; 2005 Nov; 23(33):8340-7. PubMed ID: 16293865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-associated hematopoietic toxicity.
    Kuhn JG
    Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S4-7. PubMed ID: 12166034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C.
    Dar Santos AE; Partovi N; Ford JA; Yoshida EM
    Ann Pharmacother; 2007 Feb; 41(2):268-75. PubMed ID: 17299014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
    Molineux G
    Anticancer Drugs; 2003 Apr; 14(4):259-64. PubMed ID: 12679729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegfilgrastim.
    Willis F; Pettengell R
    Expert Opin Biol Ther; 2002 Dec; 2(8):985-92. PubMed ID: 12517276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
    Henry DH
    Drugs; 2007; 67(2):175-94. PubMed ID: 17284083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.